Browse all clinical evidence, news, and expert commentary
Preclinical studies show sustained molecular responses to GLP-1 receptor stimulation in pancreatic cell models. What does that mean for primary care, and what does it not show?
New MASH licences clarify the fibrosis stages they cover, while the staging pathway remains the practical question for primary care.
A BMJ network meta-analysis of 262 trials and 99,791 participants compares 19 obesity drugs. The ranking matters less than what sits behind each position.
A triple agonist is a single peptide with activity at the GLP-1, GIP and glucagon receptors. This animation maps where each one acts and what the early trial evidence shows.
The February 2026 update to NG28 ends that era. Most newly diagnosed patients will now be offered an SGLT-2 inhibitor alongside metformin from the outset.
ATTAIN-MAINTAIN, published in Nature Medicine, shows that switching from injectable GLP-1 receptor agonists to oral orforglipron preserves over 74% of weight loss at 52 weeks.[1] Here is what the data shows and what it means for primary care.
Surgery still outperforms pharmacotherapy for sustained weight loss. The gap widens once therapy stops. A practical synthesis for UK primary care prescribers.
The EVOKE trials are in, and the answer is no. Novo Nordisk has terminated the programme and discontinued the planned one-year extension of both trials.
How GLP-1 receptor agonists drive weight loss across the brain, gut, and metabolism.
If you prescribe semaglutide, you need to know about this MHRA safety update on the risk of rare vision loss.
If it feels like your practice is increasingly dominated by patients asking for the 'miracle jab,' you aren't alone. A comprehensive primary care update on GLP-1 receptor agonists in 2026.
